Continuous Renal Replacement Therapy Market

Continuous Renal Replacement Therapy Market by Product (Disposables (Hemofilters, Bloodlines), Machine, Dialysates, Renal Replacement fluids), Modality (SCUF, CVVH, CVVHD, CVVHDF), Patient (Adult, Pediatrics, Neonates) - Global Forecast to 2026

Report Code: MD 3842 Jun, 2021, by marketsandmarkets.com

The global continuous renal replacement therapy market in terms of revenue was estimated to be worth $1.2 billion in 2021 and is poised to reach $1.7 billion by 2026, growing at a CAGR of 7.3% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Various factors such as the rise in worldwide prevalence of AKI, the growing number of ICU patients with AKI, the increasing incidence of sepsis, and the growing clinical advantage of continuous renal replacement therapy over intermittent blood purification are likely to boost the growth of the market.

Continuous Renal Replacement Therapy Market

To know about the assumptions considered for the study, Request for Free Sample Report

Continuous Renal Replacement Therapy Market Dynamics

Driver: An increase in the prevalence of acute kidney injury (AKI)

The growing worldwide incidence of AKI and AKF is, therefore, expected to increase the demand for continuous renal replacement therapy. According to the International Society of Nephrology (INR), an estimated 13.3 million cases of AKI are registered annually worldwide. This is anticipated to boost the adoption of continuous renal replacement therapy at a rapid rate. With the rapid growth in the global geriatric population, the prevalence of kidney-related diseases is expected to increase significantly. This, in turn, is expected to propel the growth of the continuous renal replacement therapy market at a significant rate during the forecast period.

Restraint: High procedural costs of continuous renal replacement therapy

As the population in emerging nations is price-sensitive, they prefer lower-priced products. Although the cost of continuous renal replacement therapy in developing countries is high, this still makes these procedures unaffordable for a large portion of the population due to their low purchasing power. This limits the demand for and uptake of continuous renal replacement therapy in both developing and developed countries.

Opportunity: Emerging markets in APAC and RoW

Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for players in the continuous renal replacement therapy market. According to a study conducted on 100 critically ill patients in a prospective observational study published in the Journal of Clinical and Diagnostic Research (JCDR) 2018, AKI was observed in 17.3 cases per 1,000 people in India. To leverage the significant growth opportunities in emerging countries, players are increasingly focusing on undertaking strategic developments to increase their presence in these markets and tap a large number of customers. Additionally, regulatory policies in the Asia-Pacific region are more adaptive and business-friendly due to the less-stringent data requirements. This, along with the increasing competition in the mature markets (Europe, Japan, and Australia), will further encourage manufacturers of continuous renal replacement therapy products to focus on the emerging markets.

Challenge: Shortage of trained ICU professionals in developing nations

Continuous renal replacement therapy is a highly specialised and critical therapy that involves complex nursing care. Properly trained ICU nurses are required for the continuous assessment of indications, ensuring good vascular access, avoiding unnecessary interruptions, and preventing complications in patients during continuous renal replacement therapy. However, currently, there is a dearth of registered nurses in ICU settings. Moreover, the complexity associated with continuous renal replacement therapy is likely to hinder market growth.

Dialysates and replacement fluids were the dominant product segment in the continuous renal replacement therapy industry.

The dominant position of this segment in the continuous renal replacement therapy market is attributed to increased market availability and demand for novel product lines for dialysates, along with the emergence of local players and startups offering cost-effective and affordable products.

Continuous venovenous hemodiafiltration (CVVHDF) segment of the continuous renal replacement therapy industry was the fastest-growing modality globally.

The high growth rate of the CVVHDF segment can be attributed to its procedural flexibility as well as other advantages, such as diffusion for the removal of solutes, as compared to other modes.

Adult patients were the larger patient segment as compared to paediatric patients in the continuous renal replacement therapy industry.

Adult and geriatric patients are the largest target group for continuous renal replacement therapy products, owing to higher prevalence and hospital admissions among them for AKI and other critical conditions, as well as the greater focus of leading players on adult and geriatric-specific product portfolios.

Asia-Pacific is the fastest-growing region in the continuous renal replacement therapy industry.

The global continuous renal replacement therapy market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2021, Asia-Pacific is reported to be the fastest-growing region owing to the increasing incidence and prevalence of AKI, the rising approval of continuous renal replacement therapy products for multiple applications, and continued government initiatives to increase awareness about the advancements in renal therapy.

Continuous Renal Replacement Therapy Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Prominent players in this market are Baxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), and Toray Medical Co., Ltd. (Japan), among others.

Scope of the Continuous Renal Replacement Therapy Industry

Report Metric

Details

Market Revenue in 2021

$1.2 billion

Projected Revenue by 2026

$1.7 billion

Revenue Rate

Poised to grow at a CAGR of 7.3 %

Market Driver

An increase in the prevalence of acute kidney injury (AKI)

Market Opportunity

Emerging markets in APAC and RoW

This research report categorizes the continuous renal replacement therapy market to forecast revenue and analyze trends in each of the following submarkets:

By Product

  • Dialysates and Replacement Fluids
  • Disposables
  • Hemofilters
  • Bloodline Sets & Tubes
  • Other Disposables
  • CRRT Systems

By Modality

  • Continuous venovenous hemofiltration (CVVH)
  • Continuous venovenous hemodiafiltration (CVVHDF)
  • Continuous venovenous haemodialysis (CVVHD)
  • Slow continuous ultrafiltration (SCUF)

By Age group

  • Adults
  • Pediatrics /Neonates

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • RoEU
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa

Recent Developments of Continuous Renal Replacement Therapy Industry

  • Fresenius Medical Care introduced its Speedswap system in American markets in 2022, allowing for the simple replacement of flow-compromising dialysis filters without the need for cartridge replacement.
  • Fresenius Medical Care, in collaboration with the National Kidney Foundation (Malaysia), launched the Kidney Health Initiative in 2022, with the goal of raising awareness among adult and paediatric patients and promoting kidney health in Malaysia.
  • In 2020, Medtronic plc announced the launch of the Carpediem system, the first and only paediatric and neonatal acute dialysis system designed to treat patients weighing 2.5–10 kg (5.5–22 pounds) requiring renal replacement therapy.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 25)
    1.1 OBJECTIVES OF THE STUDY
    1.2 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY USED FOR THE STUDY
    1.5 MAJOR MARKET STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 29)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 BREAKDOWN OF PRIMARIES: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
    2.2 MARKET ESTIMATION METHODOLOGY
           FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
           2.2.2 USAGE-BASED MARKET ESTIMATION
                    FIGURE 4 ESTIMATION OF CRRT PROCEDURES
                    FIGURE 5 MARKET SIZE ESTIMATION: GLOBAL MARKET BASED ON PRODUCT UTILIZATION METHODOLOGY
                    FIGURE 6 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY SIZE ESTIMATION: GLOBAL MARKET BASED ON REVENUE MAPPING METHODOLOGY
           2.2.3 PRIMARY RESEARCH VALIDATION
    2.3 DATA TRIANGULATION
           FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS
    2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY (Page No. - 39)
    FIGURE 8 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    FIGURE 9 GLOBAL MARKET, BY MODALITY, 2021 VS. 2026 (USD MILLION)
    FIGURE 10 GLOBAL MARKET, BY AGE GROUP, 2021 VS. 2026 (USD MILLION)
    FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET

4 PREMIUM INSIGHTS (Page No. - 43)
    4.1 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY OVERVIEW
           FIGURE 12 RISING PREVALENCE OF AKI AND GROWING AWARENESS ABOUT CRRT TO DRIVE MARKET GROWTH
    4.2 GLOBAL MARKET SHARE, BY AGE GROUP, 2021
           FIGURE 13 ADULTS SEGMENT TO DOMINATE THE GLOBAL MARKET IN 2021
    4.3 ASIA PACIFIC: MARKET, BY PRODUCT AND COUNTRY
           FIGURE 14 DIALYSATES AND REPLACEMENT FLUIDS ACCOUNT FOR THE LARGEST SHARE OF THE CRRT PRODUCTS MARKET IN THE APAC
           FIGURE 15 APAC MARKET TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021–2026)

5 MARKET OVERVIEW (Page No. - 47)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 16 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing incidence of acute kidney injury (AKI)
                               FIGURE 17 GLOBAL INCIDENCE OF AKI, 2010 VS. 2015 VS. 2020
                               TABLE 1 NUMBER OF PEOPLE AGED 65 YEARS OR OVER, BY REGION, 2019 VS. 2050
                    5.2.1.2 Growing number of ICU patients with AKI and increasing incidence of sepsis
                               FIGURE 18 IMPACT OF ICU-ACQUIRED AKI IN THE US
                    5.2.1.3 Increasing clinical advantage of CRRT over intermittent blood purification
                    5.2.1.4 Technological advancements and new product launches
                    5.2.1.5 Growing prevalence of diabetes and hypertension
                               FIGURE 19 TOP 5 COUNTRIES WITH CHILDREN AND ADOLESCENTS WITH TYPE I DIABETES, 2019
           5.2.2 RESTRAINTS
                    5.2.2.1 Stringent regulatory guidelines in North America
                    5.2.2.2 High procedural cost of CRRT
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging markets in APAC and RoW
                    5.2.3.2 Increasing applications of CRRT
                               5.2.3.2.1 Evolution of CRRT from a simple renal replacement treatment to multi-organ support therapy
                               5.2.3.2.2 Progression of CRRT from adaptive renal devices to multipurpose treatment machines
                    5.2.3.3 Ongoing research to establish the safety and efficacy profile of CRRT
                    5.2.3.4 Development of CRRT systems for pediatric patients
                               5.2.3.4.1 The CARPEDIEM Project
                    5.2.3.5 Untapped growth opportunities in North America
           5.2.4 CHALLENGES
                    5.2.4.1 High complexity of CRRT
                    5.2.4.2 Lack of standard treatment guidelines in developing nations
                    5.2.4.3 Shortage of trained ICU professionals in developing nations
                    5.2.4.4 Poor reimbursement scenario in developing countries
                    5.2.4.5 Lack of awareness about the benefits of CRRT
    5.3 GLOBAL REGULATORY LANDSCAPE
           5.3.1 NORTH AMERICA
           5.3.2 EUROPE
           5.3.3 ASIA PACIFIC
                    5.3.3.1 India
                    5.3.3.2 China
                    5.3.3.3 Japan
                    5.3.3.4 South Korea
           5.3.4 REST OF THE WORLD (ROW)
                    5.3.4.1 Brazil
                    5.3.4.2 Argentina
    5.4 GLOBAL REIMBURSEMENT SCENARIO
           5.4.1 NORTH AMERICA
           5.4.2 EUROPE
           5.4.3 ASIA PACIFIC
           5.4.4 JAPAN
           5.4.5 REST OF THE WORLD (ROW)
                    5.4.5.1 Brazil
                    5.4.5.2 Central America and the Caribbean
    5.5 COVID-19 IMPACT ON THE CRRT MARKET
           FIGURE 20 US: COVID-19 HOSPITALIZATION DATA FOR SPECIALIZED MEDICAL CONDITIONS IN ADULTS (AS OF APRIL 11, 2020)
    5.6 VALUE CHAIN ANALYSIS
           FIGURE 21 VALUE CHAIN OF THE GLOBAL MARKET
    5.7 ECOSYSTEM COVERAGE
    5.8 PRICING TREND ANALYSIS
           TABLE 2 AVERAGE PRICE OF CRRT SYSTEMS AND CONSUMABLES, BY COUNTRY, 2020 (USD)
    5.9 PORTER’S FIVE FORCES ANALYSIS
           TABLE 3 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.9.1 THREAT FROM NEW ENTRANTS
                    FIGURE 22 THREAT FROM NEW ENTRANTS
           5.9.2 THREAT FROM SUBSTITUTES
                    FIGURE 23 THREAT FROM SUBSTITUTES
           5.9.3 BARGAINING POWER OF SUPPLIERS
                    FIGURE 24 BARGAINING POWER OF SUPPLIERS
           5.9.4 BARGAINING POWER OF BUYERS
                    FIGURE 25 BARGAINING POWER OF BUYERS
           5.9.5 INTENSITY OF COMPETITIVE RIVALRY
                    FIGURE 26 INTENSITY OF COMPETITIVE RIVALRY

6 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT (Page No. - 69)
    6.1 INTRODUCTION
           TABLE 4 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY PRODUCT, 2019–2026 (USD MILLION)
    6.2 DIALYSATES & REPLACEMENT FLUIDS
           6.2.1 RISING DEMAND FOR DIALYSATES HAS SUPPORTED MARKET GROWTH
                    TABLE 5 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY MODALITY, 2019–2026 (USD MILLION)
                    TABLE 6 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
                    TABLE 7 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY REGION, 2019–2026 (USD MILLION)
    6.3 DISPOSABLES
           TABLE 8 DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 9 DISPOSABLES MARKET, BY MODALITY, 2019–2026 (USD MILLION)
           TABLE 10 DISPOSABLES MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
           TABLE 11 DISPOSABLES MARKET, BY REGION, 2019–2026 (USD MILLION)
           6.3.1 HEMOFILTERS
                    6.3.1.1 Hemofilters are widely adopted during CRRT procedures for the treatment of AKI
                               TABLE 12 HEMOFILTERS MARKET, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 13 HEMOFILTERS MARKET, BY MODALITY, 2019–2026 (USD MILLION)
                               TABLE 14 HEMOFILTERS MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
           6.3.2 BLOODLINE SETS & TUBES
                    6.3.2.1 Established players are focusing on strengthening their bloodline sets and tubes product lines
                               TABLE 15 BLOODLINE SETS & TUBES MARKET, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 16 BLOODLINE SETS & TUBES MARKET, BY MODALITY, 2019–2026 (USD MILLION)
                               TABLE 17 BLOODLINE SETS & TUBES MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
           6.3.3 OTHER DISPOSABLES
                    TABLE 18 OTHER DISPOSABLES MARKET, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 19 OTHER DISPOSABLES MARKET, BY MODALITY, 2019–2026 (USD MILLION)
                    TABLE 20 OTHER DISPOSABLES MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
    6.4 CRRT SYSTEMS
           6.4.1 INTRODUCTION OF ADVANCED PRODUCTS TO DRIVE THE DEMAND FOR CRRT SYSTEMS
                    TABLE 21 CRRT SYSTEMS MARKET, BY MODALITY, 2019–2026 (USD MILLION)
                    TABLE 22 CRRT SYSTEMS MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
                    TABLE 23 CRRT SYSTEMS MARKET BY REGION, 2019–2026 (USD MILLION)

7 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY (Page No. - 80)
    7.1 INTRODUCTION
           TABLE 24 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY MODALITY, 2019–2026 (USD MILLION)
    7.2 CONTINUOUS VENOVENOUS HEMOFILTRATION
           7.2.1 WIDESPREAD ADOPTION OF CVVH IN THE TREATMENT OF ACUTE KIDNEY INJURY TO DRIVE MARKET GROWTH
                    TABLE 25 CONTINUOUS VENOVENOUS HEMOFILTRATION MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION
           7.3.1 CVVHDF IS USED IN PATIENTS WITH CONGESTIVE HEART FAILURE
                    TABLE 26 CONTINUOUS VENOVENOUS HEMODIAFILTRATION MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.4 CONTINUOUS VENOVENOUS HEMODIALYSIS
           7.4.1 THIS THERAPY IS MORE EFFECTIVE IN REMOVING SMALL TO MEDIUM-SIZED MOLECULES AS COMPARED TO OTHER CRRT MODALITIES
                    TABLE 27 CONTINUOUS VENOVENOUS HEMODIALYSIS MARKET, BY REGION, 2019–2026 (USD MILLION)
    7.5 SLOW CONTINUOUS ULTRAFILTRATION
           7.5.1 SCUF DOES NOT USE DIALYSATES OR REPLACEMENT FLUIDS FOR THE REMOVAL OF EXCESS FLUID FROM THE BLOODSTREAM
                    TABLE 28 SLOW CONTINUOUS ULTRAFILTRATION MARKET, BY REGION, 2019–2026 (USD MILLION)

8 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP (Page No. - 86)
    8.1 INTRODUCTION
           TABLE 29 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY AGE GROUP, 2019–2026 (USD MILLION)
    8.2 ADULTS
           8.2.1 ADULTS HOLD THE LARGEST SHARE OF THE MARKET BY AGE GROUP
                    TABLE 30 GLOBAL MARKET FOR ADULTS, BY REGION, 2019–2026 (USD MILLION)
    8.3 PEDIATRICS & NEONATES
           8.3.1 HIGH PREVALENCE OF AKI IN NEONATES TO AID THE MARKET GROWTH DURING THE FORECAST PERIOD
                    TABLE 31 GLOBAL MARKET FOR PEDIATRICS & NEONATES, BY REGION, 2019–2026 (USD MILLION)

9 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION (Page No. - 90)
    9.1 INTRODUCTION
           TABLE 32 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY REGION, 2019–2026 (USD MILLION)
    9.2 EUROPE
           FIGURE 27 EUROPE: CRRT MARKET SNAPSHOT
           TABLE 33 EUROPE: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 34 EUROPE: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 35 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 36 EUROPE: MARKET, BY MODALITY, 2019–2026 (USD MILLION)
           TABLE 37 EUROPE: MARKET,  BY AGE GROUP, 2019–2026 (USD MILLION)
           9.2.1 GERMANY
                    9.2.1.1 Germany is the largest market for continuous renal replacement therapy in Europe
                               TABLE 38 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 39 GERMANY: CRRT  DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.2.2 UK
                    9.2.2.1 Rising number of sepsis cases in the UK to support market growth
                               TABLE 40 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 41 UK: CRRT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.2.3 FRANCE
                    9.2.3.1 France is the fastest-growing market for CRRT in Europe
                               TABLE 42 FRANCE: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 43 FRANCE: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.2.4 ITALY
                    9.2.4.1 Government initiatives to promote the awareness of CRRT for renal care to drive market growth
                               TABLE 44 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 45 ITALY: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION
           9.2.5 SPAIN
                    9.2.5.1 Favorable reimbursement scenario to favor market growth
                               TABLE 46 SPAIN: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 47 SPAIN: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.2.6 REST OF EUROPE
                    TABLE 48 ROE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 49 ROE: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
    9.3 NORTH AMERICA
           TABLE 50 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 51 NORTH AMERICA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 52 NORTH AMERICA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 53 NORTH AMERICA: MARKET, BY MODALITY, 2019–2026 (USD MILLION)
           TABLE 54 NORTH AMERICA: CRRT MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
           9.3.1 US
                    9.3.1.1 Large number of AKI patients in the region to drive the market growth
                               TABLE 55 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 56 US: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.3.2 CANADA
                    9.3.2.1 High cost of CRRT as compared to IHD is negatively impacting market growth in Canada
                               TABLE 57 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 58 CANADA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
    9.4 ASIA PACIFIC
           FIGURE 28 APAC: CRRT MARKET SNAPSHOT
           TABLE 59 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 60 APAC: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 61 APAC: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 62 APAC: MARKET, BY MODALITY, 2019–2026 (USD MILLION)
           TABLE 63 APAC: CRRT MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
           9.4.1 JAPAN
                    9.4.1.1 Increasing use of CRRT to boost the market in Japan
                               TABLE 64 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 65 JAPAN: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.4.2 CHINA
                    9.4.2.1 Increasing prevalence of ESRD and AKI to boost the demand for CRRT
                               TABLE 66 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 67 CHINA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Growing number of AKI patients and ICU admissions to support market growth
                               TABLE 68 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 69 INDIA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.4.4 AUSTRALIA
                    9.4.4.1 The Australian government is taking various initiatives to increase the awareness of CRRT
                               TABLE 70 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 71 AUSTRALIA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.4.5 SOUTH KOREA
                    9.4.5.1 The country is witnessing an increasing number of patients receiving CRRT for the treatment of AKI
                               TABLE 72 SOUTH KOREA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 73 SOUTH KOREA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.4.6 REST OF ASIA PACIFIC
                    TABLE 74 REST OF ASIA PACIFIC: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 75 REST OF ASIA PACIFIC: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
    9.5 LATIN AMERICA
           TABLE 76 LATIN AMERICA: CRRT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 77 LATIN AMERICA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 78 LATIN AMERICA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 79 LATIN AMERICA: MARKET, BY MODALITY, 2019–2026 (USD MILLION)
           TABLE 80 LATIN AMERICA: MARKET, BY AGE GROUP, 2019–2026 (USD MILLION)
           9.5.1 BRAZIL
                    9.5.1.1 Brazil holds the largest share in the Latin American CRRT market
                               TABLE 81 BRAZIL: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 82 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.5.2 MEXICO
                    9.5.2.1 Large patient population and growing middle-class population to support market growth in Mexico
                               TABLE 83 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 84 MEXICO: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
           9.5.3 REST OF LATIN AMERICA
                    TABLE 85 REST OF LATIN AMERICA: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 86 REST OF LATIN AMERICA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA
           9.6.1 LACK OF AWARENESS REGARDING CRRT TO RESTRAIN THE MARKET GROWTH IN THE REGION
                    TABLE 87 MEA: CRRT MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 88 MEA: CRRT DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 89 MEA: MARKET, BY MODALITY, 2019–2026 (USD MILLION)
                    TABLE 90 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY AGE GROUP, 2019–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 125)
     10.1 OVERVIEW
     10.2 KEY PLAYER STRATEGIES
     10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
               FIGURE 29 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE CRRT MARKET
     10.4 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY SHARE ANALYSIS (2020)
               TABLE 91 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEGREE OF COMPETITION
     10.5 COMPETITIVE LEADERSHIP MAPPING
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
                       FIGURE 30 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
     10.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020)
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
                       FIGURE 31 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2020
     10.7 FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY
             10.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY
                       TABLE 92 INDUSTRY FOOTPRINT OF COMPANIES
                       TABLE 93 REGIONAL FOOTPRINT OF COMPANIES
                       10.7.1.1 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY: Product launches and regulatory approvals (January 2018 to May 2021)
                                   TABLE 94 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
                       10.7.1.2 CRRT market: Deals (January 2018 to May 2021)
                                   TABLE 95 KEY DEALS
                       10.7.1.3 Continuous renal replacement therapy market: Other developments (January 2018 to May 2021)
                                   TABLE 96 KEY OTHER DEVELOPMENTS

11 COMPANY PROFILES (Page No. - 137)
     11.1 MAJOR PLAYERS
             11.1.1 BAXTER INTERNATIONAL INC.
                       11.1.1.1 Business overview
                                   TABLE 97 BAXTER INTERNATIONAL INC.: BUSINESS OVERVIEW
                                   FIGURE 32 COMPANY SNAPSHOT: BAXTER INTERNATIONAL INC.
                       11.1.1.2 Products offered
                                   TABLE 98 BAXTER INTERNATIONAL INC.: PRODUCT OFFERINGS
                       11.1.1.3 Recent developments
                       11.1.1.4 MnM view
             11.1.2 FRESENIUS MEDICAL CARE AG & CO. KGAA
                       11.1.2.1 Business overview
                                   TABLE 99 FRESENIUS MEDICAL CARE AG & CO. KGAA: BUSINESS OVERVIEW
                                   FIGURE 33 COMPANY SNAPSHOT: FRESENIUS MEDICAL CARE AG & CO. KGAA
                       11.1.2.2 Products offered
                                   TABLE 100 FRESENIUS MEDICAL CARE AG & CO. KGAA: PRODUCT OFFERINGS
                       11.1.2.3 Recent developments
                       11.1.2.4 MnM view
             11.1.3 NIKKISO CO., LTD.
                       11.1.3.1 Business overview
                                   TABLE 101 NIKKISO CO., LTD.: BUSINESS OVERVIEW
                                   FIGURE 34 COMPANY SNAPSHOT: NIKKISO CO., LTD.
                       11.1.3.2 Products offered
                                   TABLE 102 NIKKISO CO., LTD.: PRODUCT OFFERINGS
                       11.1.3.3 MnM view
             11.1.4 B. BRAUN MELSUNGEN AG
                       11.1.4.1 Business overview
                                   TABLE 103 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
                                   FIGURE 35 COMPANY SNAPSHOT: B. BRAUN MELSUNGEN AG
                       11.1.4.2 Products offered
                                   TABLE 104 B. BRAUN MELSUNGEN AG: PRODUCT OFFERINGS
                       11.1.4.3 Recent developments
                       11.1.4.4 MnM view
             11.1.5 MEDTRONIC PLC
                       11.1.5.1 Business overview
                                   TABLE 105 MEDTRONIC PLC: BUSINESS OVERVIEW
                                   FIGURE 36 COMPANY SNAPSHOT: MEDTRONIC PLC
                       11.1.5.2 Products offered
                                   TABLE 106 MEDTRONIC PLC: PRODUCT OFFERINGS
                       11.1.5.3 Recent developments
             11.1.6 ASAHI KASEI CORPORATION
                       11.1.6.1 Business overview
                                   TABLE 107 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
                                   FIGURE 37 COMPANY SNAPSHOT: ASAHI KASEI CORPORATION
                       11.1.6.2 Products offered
                                   TABLE 108 ASAHI KASEI CORPORATION: PRODUCT OFFERINGS
             11.1.7 TORAY MEDICAL CO., LTD.
                       11.1.7.1 Business overview
                                   TABLE 109 TORAY MEDICAL CO., LTD.: BUSINESS OVERVIEW
                                   FIGURE 38 COMPANY SNAPSHOT: TORAY MEDICAL CO., LTD.
                       11.1.7.2 Products offered
                                   TABLE 110 TORAY MEDICAL CO., LTD.: PRODUCT OFFERINGS
             11.1.8 NIPRO CORPORATION
                       11.1.8.1 Business overview
                                   TABLE 111 NIPRO CORPORATION: BUSINESS OVERVIEW
                                   FIGURE 39 COMPANY SNAPSHOT: NIPRO CORPORATION
                       11.1.8.2 Products offered
                                   TABLE 112 NIPRO CORPORATION: PRODUCT OFFERINGS
                       11.1.8.3 Recent developments
             11.1.9 INFOMED SA
                       11.1.9.1 Business overview
                                   TABLE 113 INFOMED SA: BUSINESS OVERVIEW
                       11.1.9.2 Products offered
                                   TABLE 114 INFOMED SA: PRODUCT OFFERINGS
                       11.1.9.3 Recent developments
                       11.1.9.4 MnM view
             11.1.10 MEDICA SPA
                       11.1.10.1 Business overview
                                   TABLE 115 MEDICA SPA: BUSINESS OVERVIEW
                       11.1.10.2 Products offered
                                   TABLE 116 MEDICA SPA: PRODUCT OFFERINGS
             11.1.11 MEDITES PHARMA SPOL. S.R.O
                       11.1.11.1 Business overview
                                   TABLE 117 MEDITES PHARMA SPOL. S.R.O: BUSINESS OVERVIEW
                       11.1.11.2 Products offered
                                   TABLE 118 MEDITES PHARMA SPOL. S.R.O: PRODUCT OFFERINGS
             11.1.12 MEDICAL COMPONENTS, INC.
                       11.1.12.1 Business overview
                                   TABLE 119 MEDICAL COMPONENTS, INC.: BUSINESS OVERVIEW
                       11.1.12.2 Products offered
                                   TABLE 120 MEDICAL COMPONENTS, INC.: PRODUCT OFFERINGS
             11.1.13 SWS HEMODIALYSIS CARE CO. LTD.
                       11.1.13.1 Business overview
                                   TABLE 121 SWS HEMODIALYSIS CARE CO. LTD.: BUSINESS OVERVIEW
                       11.1.13.2 Products offered
                                   TABLE 122 SWS HEMODIALYSIS CARE CO. LTD.: PRODUCT OFFERINGS
                       11.1.13.3 Recent developments
             11.1.14 NINGBO TIANYI MEDICAL DEVICES CO., LTD.
                       11.1.14.1 Business overview
                                   TABLE 123 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: BUSINESS OVERVIEW
                       11.1.14.2 Products offered
                                   TABLE 124 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: PRODUCT OFFERINGS
             11.1.15 ANJUE MEDICAL EQUIPMENT CO., LTD.
                       11.1.15.1 Business overview
                                   TABLE 125 ANJUE MEDICAL EQUIPMENT CO., LTD.: BUSINESS OVERVIEW
                       11.1.15.2 Products offered
                                   TABLE 126 ANJUE MEDICAL EQUIPMENT CO., LTD.: PRODUCT OFFERINGS
     11.2 EMERGING PLAYERS
             11.2.1 KIMAL
             11.2.2 JIANGXI SANXIN MEDTEC CO., LTD.
             11.2.3 ALLMED MEDICAL PRODUCTS CO., LTD.
             11.2.4 DIALCO MEDICAL INC.
             11.2.5 BROWNDOVE HEALTHCARE PVT. LTD.

12 APPENDIX (Page No. - 174)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 AVAILABLE CUSTOMIZATIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

The study involved four major activities to estimate the current size of the continuous renal replacement therapy market. Extensive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources, such as annual reports, press releases, and investor presentations of companies, white papers, certified publications, articles by recognized authors, regulatory bodies, and publications from government sources [such as the National Institutes of Health (NIH), the US Food and Drug Administration (FDA), the US Census Bureau, the World Health Organization (WHO), the American Society of Nephrology (ASN), the American Association of Kidney Patients (AAKP), and the European Renal Association] were referred to identify and collect information for the continuous renal replacement therapy market study.

Primary Research

The continuous renal replacement therapy market comprises several stakeholders, such as manufacturers of CRRT machines, CRRT disposables, dialysates, and replacement fluids, as well as market research and consulting firms. The demand side of this market is characterized by increasing AKI, growing awareness of CRRT, and an increased number of players in the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is the breakdown of primary respondents:

Continuous Renal Replacement Therapy Market Size

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the continuous renal replacement therapy market. These methods were also extensively used to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry's supply chain and market size, in terms of value, have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Continuous Renal Replacement Therapy Market Size

To know about the assumptions considered for the study, Request for Free Sample Report

Continuous Renal Replacement Therapy Market Size

Data Triangulation

After arriving at the overall size of the global continuous renal replacement therapy market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. Market data was triangulated by studying various macroindicators and regional trends from both demand- and supply-side participants.

Report Objectives

  • To define, describe, and forecast the global continuous renal replacement therapy market on the basis of product, modality, age group and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
  • To profile the key market players and comprehensively analyze their market shares and core competencies2
  • To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global continuous renal replacement therapy market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the global continuous renal replacement therapy market report

Product Analysis

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players.

Company Information

  • Detailed analysis and profiling of additional market players (up to 5 OEMs)

Geographic Analysis

  • Further breakdown of the Rest of Europe continuous renal replacement therapy market into Belgium, Austria,
  • Denmark, Greece, Poland, and Russia, among other countries
  • Further breakdown of the Rest of Asia Pacific continuous renal replacement therapy market into New Zealand, Vietnam, Philippines, Singapore, Malaysia, Thailand, and Indonesia, among other countries
  • Further breakdown of the Rest of Latin America continuous renal replacement therapy market into Argentina, and Colombia, among other countries.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 3842
Published ON
Jun, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Continuous Renal Replacement Therapy Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback